A new study examines pregnancy outcomes among women using stimulants or atomoxetine during pregnancy, finding modest increases in some complications with stimulant use while highlighting important limitations of observational data.
A large claims-based study found no increased risk for most outcomes with first-trimester stimulant exposure during pregnancy, but higher risks when use continued later in pregnancy.
In women with ADHD, about 60% of women with ADHD elect to discontinue ADHD medications around the time of conception.
A growing body of literature supports the reproductive safety of stimulants in pregnant women and suggests that not treating may have negative consequences for the mother and her child.
This preliminary study demonstrates the potential benefits of increasing the dosage of psychostimulant medication premenstrually in women with ADHD who experience premenstrual worsening of ADHD and mood symptoms.
Modafinil (brand name Provigil) and armodafinil (Nuvigil) are wake-promoting agents used to treat sleepiness due to narcolepsy, shift work sleep disorder, or obstructive sleep apnea. They are also used in other settings, often in [...]
Prenatal exposure to ADHD medications, mostly methylphenidate, was not associated with an increased risk of neurodevelopmental disorders or growth restriction in exposed children.
Many women taking stimulants question whether it is safe to take these medications while breastfeeding. Â
Women with attention-deficit/hyperactivity disorder (ADHD) often discontinue psychostimulant medications during pregnancy, especially if they have milder symptoms. While this approach makes sense in terms of limiting unnecessary exposures in women with what appears to [...]
As soon as we published this article on the use of modafinil during pregnancy, another study was published which included data on the reproductive safety of modafinil and armodafinil from the US Provigil/Nuvigil Pregnancy [...]
